TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05511571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical neural stimulation (TENS)
Description: The TENS group: TENS application was implemented by the researchers in the patient room. The conventional TENS application took 30 minutes per session. The application continued until frequency reached 100 Hz, the pulse width reached 100 μs, and the current impedance reached a point where the women felt needling or tingling according to their tolerance. Before the application, the women were asked to lie in a supine position, and the area/skin where TENS would be applied was cleaned and dried. Two electrodes of TENS were placed 2 cm above the cesarean incision, and the other two electrodes 2 cm below the incision. The women were allowed to rest during the application, and they were accompanied by the researcher. A total of five TENS sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises (PRE)
Description: The PRE group: The PRE application was implemented in the patient room. A quiet and calm environment was prepared in the room for the intervention. The PRE application was implemented by the women under the researchers' instructions. Each session lasted 30 minutes. A total of five sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held. The PRE application includes exercises based on stretching and then the relaxation of different muscle groups, accompanied by deep breathing. The exercises were carried out in the following way: First doing a deep breathing exercise and then stretching all the muscles from feet to face accompanied by breathing in, keeping the breath, and finally relaxing the muscles by breathing out at the same time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)
Description: The TENS+PRE group: The PRE and TENS applications were carried out together in this group. The administration of the interventions was the same as in groups where only TENS and only PRE applications were carried out. In this group, first, a 30-minute PRE application was implemented, which was followed by a 30-minute-TENS application.
Study: NCT03403439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Reference and Test Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Test treatment
Study: NCT02683434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping application
Description: Therapeutic taping application applied to skin affecting muscle, fascia, circulation, ligaments, tendons and joints.
Study: NCT01336140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline
Description: 75 mg of intravenous aminophylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
Study: NCT03814408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L102
Description: CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene, PGK-FANCA-WPRE
Study: NCT01776606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Dose B; dose applied to the lateral canthal lines
Study: NCT01199419

Intervention type: PROCEDURE
Intervention: comparison of PCI vs. CABG in multivessel disease
Description: invasive treatment of coronary artery disease

Intervention type: PROCEDURE
Intervention: comparison of PCI vs. CABG in multivessel disease
Description: invasive treatment of coronary artery disease
Study: NCT02002741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
Study: NCT00917618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients randomized to the control arm were instructed not to change their baseline exercise programs
Study: NCT00713544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 20 mg oral, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg, subcutaneous injection, weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 50 mg oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 100 mg oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 150 mg oral, once daily
Study: NCT02318693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 50 mg orally once a day before breakfast for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide
Description: Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
Study: NCT03050749

Intervention type: DEVICE
Group type: OTHER
Intervention: Princess® VOLUME
Description: Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
Study: NCT02396849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) Sham
Description: Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
Study: NCT01228929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Chamber Condition Change Intervention
Description: For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Chamber Condition Change Intervention
Description: For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Chamber Condition Change Intervention
Description: For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.
Study: NCT03464864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Inhalation Powder
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Inhalation Powder
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Inhalation Powder
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Inhalation Powder
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Inhalation Powder
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Inhalation Powder
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Inhalation Powder
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Inhalation Powder
Description: Single ascending dose
Study: NCT05263661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT
Description: Ligation of fistula tract between external and internal sphincter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FLAP
Description: Creation of a partial wall rectal flap to close internal opening of fistula tract
Study: NCT04219865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Compound Edaravone/Placebo Injection
Description: Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 1: Compound Edaravone/Placebo Injection
Description: Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Compound Edaravone/Placebo Injection
Description: Compound Edaravone 60mg-1200mg (containing edaravone 60 mg and 2-aminoethanesulfonic acid 1200 mg) / placebo single intravenous infusion for 30min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 2: Compound Edaravone/Placebo Injection
Description: Compound Edaravone 60mg-1200mg (containing edaravone 60 mg and 2-aminoethanesulfonic acid 1200 mg) / placebo single intravenous infusion for 30min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 3: Compound Edaravone/Placebo Injection
Description: Compound Edaravone 90mg-1800mg (containing edaravone 90 mg and 2-aminoethanesulfonic acid 1800 mg) / placebo single intravenous infusion for 30min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 3: Compound Edaravone/Placebo Injection
Description: Compound Edaravone 90mg-1800mg (containing edaravone 90 mg and 2-aminoethanesulfonic acid 1800 mg) / placebo single intravenous infusion for 30min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 4: Compound Edaravone/Placebo Injection
Description: Compound Edaravone 120mg-2400mg (containing edaravone 120 mg and 2-aminoethanesulfonic acid 2400 mg) / placebo single intravenous infusion for 30min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 4: Compound Edaravone/Placebo Injection
Description: Compound Edaravone 120mg-2400mg (containing edaravone 120 mg and 2-aminoethanesulfonic acid 2400 mg) / placebo single intravenous infusion for 30min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 5: Compound Edaravone/Placebo Injection
Description: Maximum tolerated dose of drug / placebo for a single intravenous infusion for 30 minutes three times a day at an interval of 8 h until the last dose on the morning of Day 3, after which the sequential test drug 30 mg-600 mg / placebo will be administered daily from Day 3 night Intravenous infusion, 30 minutes at 12-hour intervals until morning on Day 7
Study: NCT02568111

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon beta-1a
Description: SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
Study: NCT04219865

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 5: Compound Edaravone/Placebo Injection
Description: Maximum tolerated dose of drug / placebo for a single intravenous infusion for 30 minutes three times a day at an interval of 8 h until the last dose on the morning of Day 3, after which the sequential test drug 30 mg-600 mg / placebo will be administered daily from Day 3 night Intravenous infusion, 30 minutes at 12-hour intervals until morning on Day 7
Study: NCT01329510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One-night polysomnographic recordings
Description: One-night polysomnographic recordings before and during methylphenidate treatment.
Study: NCT03490370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-muscular stimulation using NeuroTrac MyoPlus 2/4
Description: In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.
Study: NCT02568111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a
Description: SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine tartrate
Description: Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
Study: NCT01283802

Intervention type: PROCEDURE
Intervention: INTRAOPERATIVE CHOLANGIO-ULTRASOUND
Description: Techniques are as follows:~1. Direct ultrasound exploration without any contrast agents.~2. IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);~3. IOCUS injection of an air bolus into the bile duct.
Study: NCT00003526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04775693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RE (Robotic Exoskeleton)
Description: Participants will continue to receive their prescribed standard of care physical therapy/gait training. They will also utilize the robotic exoskeleton twice a week during their inpatient stay and 3 times a week for 5 weeks as an outpatient (for outpatient, only if in the RE group). The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking. It uses sensors and participant motion to move. A licensed physical therapist will be assisting participants as they use the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RE (Robotic Exoskeleton)
Description: Participants will continue to receive their prescribed standard of care physical therapy/gait training. They will also utilize the robotic exoskeleton twice a week during their inpatient stay and 3 times a week for 5 weeks as an outpatient (for outpatient, only if in the RE group). The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking. It uses sensors and participant motion to move. A licensed physical therapist will be assisting participants as they use the device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC (standard of care)
Description: Traditional physical therapist driven gait training.
Study: NCT02337543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEO6860
Description: NEO6860 is an NCE acting as a TRPV1 antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02717910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health game
Description: Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Web page
Description: Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
Study: NCT01919437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web-Enabled Cognitive Neuropsychological Evaluation System
Study: NCT01860066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 via inhaler twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol
Description: fluticasone/salmeterol via inhaler twice a day
Study: NCT02729597

Intervention type: OTHER
Intervention: medical history
Description: The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.

Intervention type: OTHER
Intervention: medical history
Description: The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.

Intervention type: OTHER
Intervention: medical history
Description: The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.

Intervention type: OTHER
Intervention: neurological clinical examination
Description: Neurological examination will be performed at baseline and follow-up.

Intervention type: OTHER
Intervention: neurological clinical examination
Description: Neurological examination will be performed at baseline and follow-up.

Intervention type: OTHER
Intervention: neurological clinical examination
Description: Neurological examination will be performed at baseline and follow-up.

Intervention type: OTHER
Intervention: neuropsychological testing
Description: Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.

Intervention type: OTHER
Intervention: neuropsychological testing
Description: Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.

Intervention type: OTHER
Intervention: neuropsychological testing
Description: Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.

Intervention type: OTHER
Intervention: brain MRI
Description: Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.

Intervention type: OTHER
Intervention: brain MRI
Description: Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.

Intervention type: OTHER
Intervention: brain MRI
Description: Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.
Study: NCT01358266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DE-109 44 ug
Description: Low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DE-109 440 ug
Description: Medium dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DE-109 880 ug
Description: High dose
Study: NCT02924467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 Notice
Description: 1 Reminder notification via autodialer
Study: NCT04823325

Intervention type: PROCEDURE
Intervention: Orthognathic Surgery
Description: The duration for presurgical orthodontic treatment was; 7,7 ± 1,7 months.
Study: NCT01495299

Intervention type: DEVICE
Intervention: Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish
Description: Phacoemulsification (standard cataract extraction surgery)
Study: NCT02257710

Intervention type: DEVICE
Intervention: Orsiro
Study: NCT03683212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early intensive care bundle
Description: The care bundle comprises a list of items to follow and tick on a handover checklist within 4 hours of ED management:~1. Treatment of the congestion: (international guidelines and recommendations)~2. Treatment of precipitating factors~3. NIV (non-invasive ventilation) if respiratory distress with hypercapnia and pH \< 7.35 in absence of contra indication.~4. Preventive LMWH (low molecular weight heparin) if no pre-existing anticoagulation therapy.